Answer
Urine tests before and periodically during pazopanib hydrochloride treatment are recommended to detect and monitor worsening proteinuria (protein in urine), which has been reported during treatment; pazopanib should be discontinued if nephrotic syndrome develops.
Sources for this answer
- Votrient 200 mg and 400 mg film coated tabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 36Document updated
Sources checked